- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00000106
41.8 Degree Centigrade Whole Body Hyperthermia for the Treatment of Rheumatoid Diseases
June 23, 2005 updated by: National Center for Research Resources (NCRR)
Recently a non-toxic system for whole body hyperthermia (WBH) used at the University of Wisconsin has been shown to induce soluble tumor necrosis factor-receptor (sTNF-R) I and II when patients are heated systemically to 41.8C for 60 minutes.
This observation might provide a biological basis for the therapeutic application of WBH to rheumatoid diseases, for which there is a positive anecdotal clinical experience.
Inherent in the hypothesis which is the basis for this protocol is the concept that the induction of TNF receptors by WBH may induce a remission in patients with active rheumatoid arthritis.
Beyond clinical response the biological endpoint for this investigation includes cytokine levels, TNF levels, sTNF-R levels and changes in cellular TNF receptors.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- K4/666 CSC 600 Highland Av
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients are required to meet the criteria of the American College of Rheumatology (ACR)for rheumatoid arthritis.
- Patients should be in functional class II, or III according to the criteria of the ACR.
- All candidates must be unsuccessfully treated (lack of efficacy) with at least two of the following disease-modifying antirheumatic drugs: hydroxychloroquinine, oral or injectable gold, methotrexate, azathioprine, penicillamine, and sulfasalazine.
- Patients receiving nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids (<= 10 mg per day), or both are eligible if the dosage has been stable for at least four weeks before treatment and remained so throughout the study and follow-up period (the use of narcotics for pain flares is allowed).
- The necessary degree of disease activity at enrollment should be confirmed by a finding of 10 or more swollen joints, 12 or more tender joints, and one of the following two criteria: a Westergren erythrocyte sedimentation rate of at least 28 mm per hour or a serum C-reactive protein level of more than 2.0 mg per deciliter; or morning stiffness for at least 60 minutes.
- Patients must have adequate bone marrow function, adequate liver function, adequate renal function, calcium and electrolytes.
- Patients must have a dobutamine stress ECHO, or exercise cardiac MUGA, or exercise ECHO scan prior to entry and must fulfill certain criteria to be eligible. The spirit of the criteria are to rule out organic heart disease.
- Respiratory status: Patients who have FEV1 of >= 60% of predicted, as well as a maximum voluntary volume (MVV) of >= 60% of predicted, and blood gases with a PO2 of >= 60 or oxygen saturation of >= 90% are eligible.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
January 18, 2000
First Submitted That Met QC Criteria
January 18, 2000
First Posted (Estimate)
January 19, 2000
Study Record Updates
Last Update Posted (Estimate)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
November 1, 2000
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCRR-M01RR03186-9943
- M01RR003186 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatic Diseases
-
Xijing HospitalAir Force Military Medical University, ChinaUnknownRheumatic Valve DiseaseChina
-
Assiut UniversityNot yet recruitingRheumatic Mitral Valve Disease
-
Assiut UniversityRecruitingFollow up of Moderate Aortic Regurge After Rheumatic Mitral Valve ReplacementEgypt
-
Paris Cardiovascular Research Center (Inserm U970)Not yet recruitingRheumatic Heart Disease in Children
-
Duke UniversityChildhood Arthritis and Rheumatology Research AllianceRecruitingRheumatic Joint DiseaseUnited States, Canada, Israel, Italy, Puerto Rico
-
Children's National Research InstituteUniversity of Cape Town; Thrasher Research Fund; Murdoch Childrens Research Institute and other collaboratorsUnknownHeart Diseases | Rheumatic Heart Disease | Rheumatic Heart Disease in Children | Latent Rheumatic Heart DiseaseUganda
-
Centre Hospitalier Universitaire de NiceCompleted
-
Ettore Sansavini Health Science FoundationUnknownTricuspid (Valve) Insufficiency (Rheumatic)Italy
-
University Hospital Inselspital, BerneInstituto de Cardiología Paredes-Horna, Arequipa; Hospital Nacional Carlos...CompletedRheumatic Heart Disease | Acute Rheumatic FeverPeru, Switzerland
-
University Hospital Inselspital, BerneRecruitingRheumatic Heart Disease | Rheumatic Heart Disease in ChildrenNepal
Clinical Trials on Whole body hyperthermia unit
-
Universität Duisburg-EssenCompletedDepression, UnipolarGermany
-
Massachusetts General HospitalUniversity of California, San FranciscoNot yet recruiting
-
University of ArizonaBrain & Behavior Research Foundation; The Depressive and Bipolar Disorder Alternative... and other collaboratorsCompleted
-
Charite University, Berlin, GermanyRecruiting
-
Massachusetts General HospitalNational Institute of General Medical Sciences (NIGMS)RecruitingInflammation | Hyperthermia | Major Depressive DisorderUnited States
-
Massachusetts General Hospitalheckel medizintechnik GmbHNot yet recruitingMajor Depressive Disorder
-
Vail Health Behavioral HealthSteadman Philippon Research InstituteNot yet recruitingDepression | Mood DisordersUnited States
-
University of California, San FranciscoNational Center for Complementary and Integrative Health (NCCIH)RecruitingDepression | Major Depressive DisorderUnited States
-
ElmediXRecruitingAdvanced Cancer | Pancreatic Cancer MetastaticBelgium
-
Charles (Chuck) RaisonWithdrawnFibromyalgiaUnited States